An antioxidant nanodrug protects against hepatic ischemia–reperfusion injury by attenuating oxidative stress and inflammation

CeO 2 and MnO 2 nanocomposites, with advantages of high biocompatibility, passive liver-targeting and short-term metabolic excretion, have the capacity to scavenge ROS and regulate the inflammation to alleviate hepatic ischemia–reperfusion injury.